CStone Pharmaceuticals Doses First Patient in CS2009 Phase I Study for Solid Tumors
China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase...
Drug
Laekna’s LAE120 Receives FDA Approval for Solid Tumor Clinical Trials
Sino-US biotech company Laekna, Inc. (HKG: 2105) announced that it has received clinical trial approval...
SynerK’s SNK-2726 Gets FDA Green Light for Phase I Hypertension Study
SynerK, an RNA-targeted therapy developer with operations in Boston, US, and Beijing and Suzhou, China,...
Innovent Biologics Doses First Patient in IBI363 Melanoma Study vs Keytruda
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the pivotal regulatory...
Eyebright Medtech Plans Private Placement to Expand Contact Lens Production
China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050), an ophthalmic medical device manufacturer, announced...
Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from...
AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study
AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase...
CARsgen’s CT041 Awarded Breakthrough Therapy Designation for Gastric Cancer
CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that its chimeric antigen receptor (CAR) T-cell therapy,...
CSPC Pharmaceutical’s Sirolimus Receives BTD for Malignant PEComa Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received Breakthrough Therapy Designation...
Fosun Pharmaceutical’s XS-03 Gets NMPA Green Light for CRC Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...
Bayer’s BlueRock Therapeutics Gets Fast Track for OpCT-001 Therapy
German pharmaceutical giant Bayer (ETR: BAYN) and its wholly owned subsidiary BlueRock Therapeutics LP announced...
Chipscreen Biosciences’ CS12088 Gets NMPA Clearance for Hepatitis B Study
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that the National Medical Products Administration...
Hengrui Pharmaceuticals Gets NMPA Green Light for SHR-A2009 Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that the National Medical Products Administration...
Akeso Inc. Completes Patient Enrollment for AK138D1 Phase I Study
China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the Phase...
CARsgen Therapeutics Administers KJ-C2219 in SLE Patient in IIT
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at...
Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer
China-based Adagene Inc. (NASDAQ: ADAG) announced the initiation of an Investigator-Initiated (IIT) Phase II trial...
Shanghai Moyang Biotech’s Aphranel CC Needle Wins NMPA Approval
China-based Shanghai Moyang Biotechnology Co., Ltd, an innovation-focused company in nanomedical biomaterials and Class III...
Huadong Medicine’s ADC HDM2005 Granted FDA Orphan Drug Designation for MCL
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its antibody-drug conjugate (ADC) HDM2005 has...
AstraZeneca’s Camizestrant Shows Promise in SERENA-6 Breast Cancer Study
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) announced positive interim analysis results from the Phase III...
Bayer’s Gadoquatrane Shows Positive Results in Phase III QUANTI CNS Study
German pharmaceutical giant Bayer (ETR: BAYN) announced positive results from the Phase III QUANTI CNS...